TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ).
Jiangsu Hengrui Pharmaceuticals Co., Ltd. has announced a board meeting scheduled for August 20, 2025, to discuss and approve the interim financial results for the first half of the year. This meeting is significant as it will provide insights into the company’s financial health and operational performance, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (HK:1276) stock is a Buy with a HK$80.57 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a leading pharmaceutical company based in China, primarily involved in the development, manufacturing, and distribution of pharmaceutical products. The company focuses on providing innovative and high-quality healthcare solutions to meet the needs of the global market.
Average Trading Volume: 5,973,514
Current Market Cap: HK$447B
For a thorough assessment of 1276 stock, go to TipRanks’ Stock Analysis page.